A New Chapter for Ibogaine: Trump Announces Federal Action
In 1993, the FDA authorized the first human study of ibogaine through an Investigational New Drug application led by pioneering researcher Dr. Deborah Mash at the University of Miami. The research began, but funding ran out, and its development in the U.S. stalled. Ibogaine did not disappear. Patients continued seeking treatment abroad, while clinicians and […]
Courtney Barnes: 4 Years After Ibogaine: What No One Tells You
Four years ago this week, Courtney Barnes walked into Beond as one of the country’s leading psychedelic policy attorneys. Talia Eisenberg and Courtney Barnes discuss the part of the ibogaine story that rarely gets told: everything that happens after. The conversation covers preparation and what she wishes she had done differently, the long work of […]
The Future of Ibogaine: A Conversation with Dr. Mark Hyman and Dr. Dalibor Sames
We were honored to see Dr. Mark Hyman and Dr. Dalibor Sames take the stage at Summit at Sea for a fascinating conversation about the future of ibogaine research and its potential role in medicine. Dr. Hyman, a pioneer in functional medicine, and Dr. Sames, a Columbia University chemist who has spent nearly three decades […]
Ibogaine Uncovered Podcast: Melissa Pruett on Motherhood, Identity & Self-Worth
“I really thought I had lost myself.” Motherhood transformed Melissa Pruett’s life in beautiful ways, but it also brought an identity shift she never expected. One year postpartum, she found herself struggling with perfectionism, postpartum depression, and wondering where the woman she once knew had gone. In our newest episode of Ibogaine Uncovered, Melissa shares […]
Hilda Sánchez: What Safety Actually Looks Like Inside Ibogaine Treatment
Hilda Sánchez has been quietly doing some of the most important work at Beond since she joined the team. She came from traditional hospital medicine, where the job is to intervene, stabilize, and move to the next patient, then she walked into a psychedelic treatment center and everything she knew about nursing got turned inside […]
Beond in the National Press: Context Behind the Coverage
Following President Trump’s April 18 executive order on psychedelic-assisted therapies, ibogaine has received increased attention in national conversations around mental health, addiction, veteran care, research, and medical access. This does not mean ibogaine has been legalized or approved in the United States. But it does mark a shift in how ibogaine is being discussed at […]
Tobias Erny: Can Ibogaine Help Parkinson’s Disease?
Parkinson’s disease has no cure, but ibogaine may be quietly rewriting what’s possible for the 11 million people living with it. Today on Ibogaine Uncovered, Talia Eisenberg talks with Tobias Erny, a researcher and practitioner with nearly two decades of experience working with iboga, about the science, the stories, and the honest limits of this […]
Lorna Sturchio: How Ibogaine Helped a Navy Veteran Heal Trauma, TBI, and Addiction
Women veterans face a war that never makes the headlines, one fought inside the ranks against sexual assault, toxic leadership, and a system that demands silence. Lorna Sturchio served six years in the U.S. Navy, survived two deployments, and came home to battle invisible wounds that no amount of medication could reach. In this episode, […]
Beond CEO Tom Feegel Quoted in Official White House Release on Ibogaine
This is not legalization. But it is another major signal that ibogaine is now being taken seriously at the highest levels of government. Following President Trump’s April 18 executive order on psychedelic-assisted therapies, the White House published an official release highlighting support from veterans’ groups, advocacy organizations, industry leaders, and policymakers. Among those quoted was […]
What Trump’s New Executive Order Means for Ibogaine
Today marks an important moment in the U.S. conversation around ibogaine, especially for veterans, families, and patients who have exhausted conventional options without meaningful relief. President Donald Trump signed an executive order directing federal agencies to accelerate review pathways for certain psychedelic therapies, including ibogaine compounds. This does not mean ibogaine is approved in the […]